Corgi ETF Trust I - Corgi ONTO 2x Daily ETF (ONTX)
| Assets | n/a |
| Expense Ratio | n/a |
| PE Ratio | n/a |
| Shares Out | 10,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 5,215 |
| Open | 26.00 |
| Previous Close | 29.33 |
| Day's Range | 24.65 - 26.53 |
| 52-Week Low | 24.00 |
| 52-Week High | 35.20 |
| Beta | n/a |
| Holdings | n/a |
| Inception Date | Jun 24, 2026 |
About ONTX
Corgi ETF Trust I - Corgi ONTO 2x Daily ETF is an exchange traded fund launched and managed by Corgi Strategies, LLC. It invests in public equity and fixed income markets of the United States. For its equity portion, the fund invests directly and through derivatives in stocks of companies operating semiconductor sectors. It invests in growth and value stocks of companies across diversified market capitalization. For its fixed income portion, the fund invests directly and through derivatives in cash and cash equivalents and U.S. Treasury bills. The fund uses derivatives such as swaps to create its portfolio. Corgi ETF Trust I - Corgi ONTO 2x Daily ETF is domiciled in the United States
News
Traws Pharma Announces New Employee Inducement Grants
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection ...
Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024
NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...
Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa...
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developin...
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational ...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develop...
Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models
Onconova Expands Leadership Team with Two Key Appointments
Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX...
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developi...
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care Narazaciclib ...
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa Trial in Progr...
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m.
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and develo...
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
Collaboration builds off clinical data demonstrating rigosertib's activity against PLK1 and may inform a precision medicine approach towards rigosertib's evaluation in new indications
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
NEWTOWN, Pa., March 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference
Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib's Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
Two of two evaluable participants in an ongoing investigator-sponsored program of rigosertib in RDEB-associated squamous cell carcinoma (SCC) have achieved a complete response of all cancerous skin le...
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors
NEWTOWN, Pa., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel product...
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, November 14, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, November 14, 2022
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022
NEWTOWN, Pa., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...
Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel produc...
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022
Onconova Therapeutics Announces Key Management Promotions
Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib's Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
In vitro and cell-based assays suggest narazaciclib's inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6 inhibitors In vitro and cell-based assays suggest nar...
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today
Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting
NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patient...
Onconova Therapeutics to Present at the Next Generation Kinase Inhibitors Summit
NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patient...
Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, March 17, 2022
Onconova Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
NEWTOWN, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Appoints Adar Makovski Silverstein, Ph.D., as Director, Corporate Development
NEWTOWN, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients...
Onconova Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today
Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock
NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel product...
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat canc...
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat canc...
Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12. Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12.
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
Expansion of trial underway at highest dose in the current protocol, and continued dose escalation under consideration
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement
NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients w...